Overview

This Coverage Policy addresses reduction mammoplasty for symptomatic macromastia and breast reduction surgery on the nondiseased/contralateral breast following a mastectomy or lumpectomy.

Coverage Policy

Coverage for reduction mammoplasty varies across plans. Please refer to the customer's benefit plan document for coverage details.

Breast reduction surgery on the nondiseased/contralateral breast when performed to produce a symmetrical appearance following a mastectomy or lumpectomy is considered medically necessary.

If coverage for reduction mammoplasty is available, the following conditions of coverage apply:

Reduction mammoplasty is considered to be medically necessary for the treatment of macromastia (i.e., large breasts) in women at least 18 years of age, or with completed breast growth, when ALL the following criteria are met:
• macromastia is causing at least ONE of the following conditions/symptoms that has been unresponsive to medical management:
  ➢ shoulder, upper back/neck pain, and/or ulnar nerve palsy for which no other etiology has been found on appropriate evaluation
  ➢ intertrigo, dermatitis, eczema, or hidradenitis at the inframammary fold
• preoperative photographs confirm the presence of:
  ➢ significant breast hypertrophy
  ➢ shoulder grooving from bra straps and/or intertrigo (if stated to be present)
• average grams of tissue to be removed per breast are above the 22nd percentile on the Schnur Sliding Scale (see Appendix A) based on the individual's body surface area (BSA) or regardless of BSA, more than 1 kg of breast tissue will be removed per breast

Reduction mammoplasty for either of the following indications is considered cosmetic in nature and not medically necessary:

• Surgery is being performed to treat psychological symptomatology or psychosocial complaints, in the absence of significant physical, objective signs.
• Surgery is being performed for the sole purpose of improving appearance.

Reduction mammoplasty is considered not medically necessary for either of the following:

• As part of a staged procedure before mastectomy.
• Known BRCA1, BRCA2, p53 or PTEN mutation confirmed by genetic testing in the absence of symptomatic macromastia meeting the above medical necessity criteria.

Suction lipectomy or ultrasonically-assisted suction lipectomy (liposuction) as a sole method of treatment for symptomatic macromastia because such treatment is considered unproven in the treatment of symptomatic macromastia.

General Background

Macromastia (i.e., female breast hypertrophy) is the development of abnormally large breasts. Normal breast development begins at approximately five weeks’ gestation and continues until a woman is in her early twenties, with the rate of development and degree of asymmetry often varying. Spontaneous massive growth of the breasts during puberty and adolescence is thought to be the result of excessive end-organ sensitivity to gonadal hormones. It is more commonly bilateral, often occurs over a brief period, and most commonly affects adolescent girls. Management is individualized and may range from reassurance or the use of supportive brassieres. It is recommended that surgery be delayed until late adolescence to allow complete breast development (Conner and Merritt, 2020, McGrath and Pomerantz, 2012).

The presence of macromastia may cause clinical manifestations when the excessive breast weight adversely affects the supporting structures of the shoulders, neck and trunk. Increased weight on the shoulders can cause pain, fatigue in the cervical and thoracic spine, which can lead to poor posture, thoracic kyphosis and occipital headaches. Grooving or ulceration of the skin on the shoulders, pressure on the brachial plexus causing neurological symptoms in the arms and skin conditions occurring at the inframammary fold such as intertrigo, dermatitis, eczema, or hidradenitis (inflammation of the apocrine sweat glands resulting in obstruction of the ducts) may also exist. The presence of these persistent signs and painful symptoms distinguish macromastia from large, normal breasts and may prompt the need for surgical intervention (McGrath and Pomerantz, 2012; American Society of Plastic Surgeons [ASPS], 2011/2017; Schnur, et al., 1997).

Medical management of conditions/symptoms may include any of the following: weight loss, acupuncture, massage therapy, chiropractic treatment, adequate bra support (proper fit and wide strap support): nonsteroidal anti-inflammatory drugs (NSAIDS)/analgesia; and physical therapy, when a functional impairment exists (Hansen, et al., 2019; Collins, et al., 2002).
Reduction mammoplasty is the surgical excision of a substantial portion of the breast, including the skin and the underlying glandular tissue, until a clinically normal size is obtained. Relocation of the nipple, which may result in decreased sensation and altered lactation, may also be required during this procedure. Therefore, it has been recommended that surgery should not be performed on an individual until the breasts are fully developed. Complications range from mild to severe and may be early or late. The most common early complication independent of reduction technique is delayed wound healing. Late complications can include, but are not limited to, seroma, scars and pseudoptosis. A BMI ≥30 kg/m^2 and smoking may increase the risk of complications.

Persons who are obese or irradiated are more likely to develop infections, and smokers experienced a higher incidence of wound dehiscence than did nonsmokers (Zhang, et al., 2016; McGrath and Pomerantz, 2012; Nahai, et al., 2008; Greydanus, et al., 2006).

The available techniques for breast reduction differ according to the pattern of skin resection, as well as the method for removing breast tissue and moving the nipple. Factors identified on the preoperative breast evaluation that are used for determining the best approach include preoperative breast size and degree of ptosis, desired postoperative breast size, skin quality, and a history of prior breast surgery. Among these, preoperative breast size and estimated breast reduction volume are the most important factors influencing the technique selected. Generally, breast hypertrophy is stratified according to the estimated volume to be resected:

- small reductions remove 200 to 400 grams per side
- moderate reductions remove 400 to 700 grams per side
- large reductions remove 700 to 1200 grams per side
- reductions in patients with gigantomastia involve massive reductions of more than 1200 grams per side

Several methods are available to help surgeons estimate breast resection volumes. The two most common methods are the Schnur sliding scale and the Descamps formula. The Schnur sliding scale estimates resection weight based on the patient's body surface area. The Descamps method estimates resection volume based on a regression analysis (Hansen, et al., 2019).

The Schnur Sliding Scale is an evaluation tool that may be used to determine the appropriate amount of tissue to be removed compared to a patient's total body surface area (BSA). This can be instrumental in determining if breast reduction is being planned for a purely cosmetic reason or as a medically necessary procedure. In a survey of plastic surgeons, Schnur et al. (1991) concluded that women whose removed breast weight was less than the 5th percentile sought the procedure for cosmetic reasons and all women whose breast weight was greater than the 22nd percentile sought the procedure for medical reasons. A calculation for BSA is: BSA (in m^2) = [(height (cm)) ^ 0.718 X (weight (kilograms [kg])) ^ 0.427 X 0.007449].

Generally, most patients do not require hospitalization after breast reduction surgery. An overnight stay with observation may be necessary for some women with medical comorbidities. Patients who experience severe postoperative nausea and vomiting may require extended observation or admission for intravenous fluid therapy and antiemetics (Hansen, et al., 2019).

Breast tissue regrowth following initial breast reduction in adolescence has been reported (Greydanus, et al., 2006). The growth of the female breast is generally described by five stages referred to as Tanner stages or sexually maturity rating (SMR) stages. A number of clinical correlations are noted with the SMR stages, including the timing of breast reduction at stage V (i.e., mature stage) (DeSilva, et al., 2006). In a review of elective plastic surgical procedures in adolescence, McGrath and Schooler (2004) stated “Breast development is variable but usually plateaus at 15–16 years of age. Reduction mammoplasty is postponed until breast maturity is reached. Occasionally, surgery is considered earlier when severe symptoms are encountered; there is a risk of recurrent hypertrophy, however.” In general, breast maturity should have been reached prior to considering breast reduction surgery.

Reduction mammoplasty has been proposed for an individual with a known BRCA1, BRCA2, p53 or PTEN mutation in the absence of symptomatic macromastia or as a part of staged procedure before mastectomy. There is a paucity of evidence in the peer-reviewed scientific literature addressing these indications. The 2019 National Comprehensive Cancer Network® (NCCN®) guideline on Breast Cancer Risk Reduction states that risk-reducing mastectomy should generally be considered only in women with a genetic mutation conferring a high
risk for breast cancer. The NCCN guideline does not address reduction mammoplasty for an individual with a known BRCA1, BRCA2, p53 or PTEN mutation or reduction mammoplasty as part of a staged procedure before mastectomy.

Literature Review
Controlled clinical studies assessing the effectiveness of surgical removal of modest amounts of breast tissue in reducing neck, shoulder, and back pain and related disabilities in women are lacking. Despite the lack of controlled studies, reduction mammoplasty has become the standard of care for a subset of individuals with symptomatic macromastia. Evidence suggests that calculating breast reduction in correlation to each patient’s body weight and height can have an effect on reducing preoperative signs and persistent physical conditions. (Cunningham, et al., 2005; Blomqvist, et al., 2004; Souto, et al., 2003; Collins, et al., 2002; Ayhan, et al., 2002; Bruhlmann, et al., 1998).

Chadbourne et al. (2001) conducted a systematic review and meta-analysis of 29 studies of 4173 patients to determine whether reduction mammoplasty improves measurable outcomes in women with breast hypertrophy. Experimental and observational studies were included; no randomized controlled trials were found. Outcomes assessed were postoperative physical signs and symptoms such as shoulder pain, shoulder (bra strap) grooving, and quality-of-life domains, such as physical and psychological functioning, and were expressed primarily as risk differences. The mean body mass index of the patients was 27.5 kg/m² in the observational studies and 29.6 kg/m² in the experimental studies. The average tissue mass removed per breast was approximately 1400 grams. The authors concluded that reduction mammoplasty was associated with a statistically significant improvement in physical signs and symptoms involving shoulder pain, shoulder grooving, upper/lower back pain, neck pain, intertrigo, breast pain, headache, and pain/numbness in the hands. The quality-of-life parameter of physical functioning was also statistically significant, while psychological functioning was not significant. The evidence suggests that women undergoing reduction mammoplasty for breast hypertrophy have significant postoperative improvement in preoperative signs and symptoms, quality of life, or both.

Breast Reduction by Liposuction
Suction lipectomy or ultrasonically-assisted suction lipectomy (liposuction) as a sole procedure has been introduced as an alternative method in reducing breast size. The effectiveness of liposuction, in terms of removing glandular breast tissue, rather than fatty tissue in the breast, remains to be demonstrated. Evidence supporting the effects of this approach on patient outcomes has been limited to retrospective/prospective uncontrolled studies and case series, and there are minimal long-term data comparing this technique to the standard surgical approach (Hayes, 2019; Maskovitz, et al., 2007; Sadove, et al., 2005).

A recent Hayes Search and Summary on reduction mammoplasty by liposuction alone concluded that there is insufficient published evidence to assess the safety and/or impact on health outcomes or patient management of liposuction as a stand-alone procedure for reduction mammoplasty in patients with macromastia (Hayes, 2019).

Professional Societies/Organizations
American Society of Plastic Surgeons (ASPS): The 2011 update (reaffirmed 2017) to the 2002 ASPS policy statement, insurance coverage criteria for third-party payors for reduction mammoplasty, recommends that justification for reduction mammoplasty should be based on the probability of relieving the clinical signs and symptoms of macromastia, not the degree of breast hypertrophy present (cup size or amount of tissue removed). Symptomatic breast hypertrophy is defined as a syndrome of persistent neck and shoulder pain, painful shoulder grooving from brassiere straps, chronic intertriginous rash of the inframammary fold, and frequent episodes of headache, backache, and neuropathies caused by heavy breasts caused by an increase in the volume and weight of breast tissue beyond normal proportions. These policy recommendations are based on the 2011 ASPS evidence based companion guideline for Reduction Mammoplasty.

Appendix A
Schnur Sliding Scale

<table>
<thead>
<tr>
<th>Body Surface Area and Cutoff Weight of Breast Tissue Removed</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Breast Reduction (gm)</strong></td>
</tr>
<tr>
<td>Body Surface Area (m²)</td>
</tr>
<tr>
<td>-----------------------</td>
</tr>
<tr>
<td>1.35</td>
</tr>
<tr>
<td>1.40</td>
</tr>
<tr>
<td>1.45</td>
</tr>
<tr>
<td>1.50</td>
</tr>
<tr>
<td>1.55</td>
</tr>
<tr>
<td>1.60</td>
</tr>
<tr>
<td>1.65</td>
</tr>
<tr>
<td>1.70</td>
</tr>
<tr>
<td>1.75</td>
</tr>
<tr>
<td>1.80</td>
</tr>
<tr>
<td>1.85</td>
</tr>
<tr>
<td>1.90</td>
</tr>
<tr>
<td>1.95</td>
</tr>
<tr>
<td>2.00</td>
</tr>
<tr>
<td>2.05</td>
</tr>
<tr>
<td>2.10</td>
</tr>
<tr>
<td>2.15</td>
</tr>
<tr>
<td>2.20</td>
</tr>
<tr>
<td>2.25</td>
</tr>
<tr>
<td>2.30</td>
</tr>
<tr>
<td>2.35</td>
</tr>
<tr>
<td>2.40</td>
</tr>
<tr>
<td>2.45</td>
</tr>
<tr>
<td>2.50</td>
</tr>
<tr>
<td>2.55</td>
</tr>
</tbody>
</table>

**Schnur Sliding Scale (Schnur, et al., 1991)**

**Centers for Medicare & Medicaid Services (CMS)**
- National Coverage Determinations (NCDs): No NCDs found.
- Local Coverage Determinations (LCDs): Multiple LCDs. Refer to the LCD table of contents link in the reference section.

**Use Outside of the US**
No relevant information.

**Coding/Billing Information**

**Note:**
1) This list of codes may not be all-inclusive.
2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>19318</td>
<td>Reduction mammaplasty</td>
</tr>
</tbody>
</table>

**Considered Unproven when performed as a sole method of treatment for symptomatic macromastia:**

<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>15877</td>
<td>Suction assisted lipectomy; trunk</td>
</tr>
</tbody>
</table>

References


18. Hansen J, Chang S. Overview of breast reduction. Last updated April 30, 2019. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA


“Cigna Companies” refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Cigna Behavioral Health, Inc., Cigna Health Management, Inc., QualCare, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2019 Cigna.